2.1. Study Design
The study was a randomized digital cross-over trial. Participants received test materials by shipment, installed a mobile app for data collection, and virtually completed two test sessions. Test sessions were separated by a 7-day washout period and participants were given the option to complete a session the next day if not available on the original test date. The informed consent form was signed online before participation. The study was registered at ClinicalTrials.gov (NCT05287516) and the study protocol was reviewed and approved by the Solutions Institutional Review Board (protocol #2022/03/11).